Oral sustained-release tablet

Abstract

An oral sustained-release tablet is provided, which does not cause initial rapid increases in the bloodlevels of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide (KRP-197) and can maintain constant the blood levels. (Solving means) An oral sustained-release tablet comprises a pharmaceutical composition and a gel-forming material, the pharmaceutical composition containing KRP-197 as an active ingredient.

1 . An oral sustained-release tablet comprising a pharmaceutical composition and a gel-forming material, the pharmaceutical composition containing 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as an active ingredient.  
   
   
       2 . The oral sustained-release tablet according to  claim 1 , wherein the gel-forming material is hydroxypropylmethylcellulose.  
   
   
       3 . The oral sustained-release tablet according to  claim 1 , wherein the pharmaceutical composition contains 18 to 73 wt % of hydroxypropylmethylcellulose.  
   
   
       4 . The oral sustained-release tablet according to  claim 1 , obtained by mixing a granular composition containing 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide with a composition containing a gel-forming material.  
   
   
       5 . The oral sustained-release tablet according to  claim 4 , wherein 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide containing granules are manufactured by using a solution of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide.